Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A3 A*01:01 TCR-T
- Development stage
- Unknown
- Lead developer
- Anocca
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MAGE-A3 A*01:01 TCR-T is an autologous T-cell receptor engineered T-cell (TCR-T) therapy developed by Anocca. The therapy utilizes patient-derived T cells that are genetically modified to express a specific T-cell receptor (TCR) designed to recognize a peptide from the Melanoma-associated antigen 3 (MAGE-A3) presented by the HLA-A*01:01 molecule. MAGE-A3 is a cancer-testis antigen that is frequently overexpressed in various solid tumors, including melanoma and non-small cell lung cancer, while remaining largely absent in healthy adult tissues. By targeting this specific peptide-HLA complex, the engineered T cells can selectively identify and eliminate malignant cells. The program is currently in Phase 1 clinical development for the treatment of MAGE-A3-positive, HLA-A*01:01-positive cancers.
- Other names
- Anocca MAGE-A3 A*01:01 TCR-TMAGE-A3 TCR-T cell therapyMAGE-A-3 TCR-T cell therapyMAGE-A 3 TCR-T cell therapyAnocca-MAGE-A3 (presented on HLA-A*01:01)-TCR-T
02
Targets
HLA-A*01 (Human leukocyte antigen A*01:01)MAGE-A12/HLA-A*01:01 (Melanoma-associated antigen 12 peptide presented by Human Leukocyte Antigen A*01:01)MAGE-A2/HLA-A*01:01 (Melanoma-associated antigen A2 (MAGE-A2) peptide presented by Human leukocyte antigen A*01:01 (HLA-A*01:01))MAGE-A6/HLA-A*01:01 (Melanoma-associated antigen 6 peptide presented by Human Leukocyte Antigen A*01:01)
Beyond the preview
Go deeper on MAGE-A3 A*01:01 TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A3 A*01:01 TCR-T.